RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
Zai Lab is planning to list its shares on the Hong Kong exchange, according to unnamed sources, in a transaction that could raise up to $300 million. One year ago, the company completed a $172 million NASDAQ debut offering. Zai is following the lead of BeiGene, which raised $900 million in Hong Kong after initially listing on NASDAQ. The Zai transaction is expected to be 10% to 20% of its expanded share base; it currently has a market capitalization of $1.2 billion.
Source: China Biotoday
